Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 363

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 363
---
, 2024. The Merger closed on February 14, 2024 (the “Closing”), at which time the following
occurred:

| 1. | The outstanding shares of Predecessor’s Preferred Stock were converted into 44,155 shares of Common 
 Stock, par value $0.0001 per share (the “Common Stock”), valued at $21,635,926.                     |

| 2. | The outstanding shares of Predecessor’s common stock were converted into 5,845 shares of Common 
 Stock, valued at $2,864,074.                                                                    |

| 3. | Each holder of Predecessor’s common stock received a pro rata portion of up to 12,000 earnout shares of restricted Common Stock (the “BCA Earnout Shares”), valued at $5,880,000, 10,000 of which are subject to vesting upon the achievement of certain stock price-based earnout targets and 2,000 of which are subject to vesting upon a change of control, respectively. |

| 4. | Certain holders of Predecessor’s common stock received a pro rata portion of 8,750 earnout shares of Common Stock (the “Reallocation Shares”), valued at $4.29 million, which became fully vested upon the Closing. |

| 5. | Certain holders of Predecessor’s common stock and convertible bridge notes received a pro rata portion                                    
 of 10,000 earnout shares (the “IND Earnout shares”) of restricted Common Stock, valued at $4,900,000, which vested when the               
 Company filed an investigational new drug (“IND”) application with the Food and Drug Administration (“FDA”). The                          
 earning of these shares was accompanied by a forfeiture of 10,000 restricted shares of Common Stock held by the sponsor following receipt 
 of an acknowledgement notice by the Sponsor.                                                                                              |

| 6. | Each outstanding Predecessor option was converted into an option to                                                                   
 purchase a number of shares of Common Stock, equal to the Predecessor’s common stock underlying the option multiplied by the Exchange 
 Ratio factor of 0.064452, at an exercise price per share equal to the Predecessor option exercise price divided by the Exchange Ratio 
 factor.                                                                                                                               |

| 7. | Each warrant to purchase the Predecessor’s preferred stock was converted into a warrant to acquire                                         
 a number of shares of Common Stock obtained by dividing the warrant as-if